Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Head and neck cancer; Intensity-modulated radiation therapy; RapidArc; Volumetric-modulated arc therapy; Tomotherapy; Cetuximab; Toxicity; Efficacy
مقالات ISI ستوکسیمب، اِربیتاکس، ستوکسیمب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Cetuximab; Elderly; Metastatic colorectal cancer; Panitumumab; Review
Automated flow fluorescent noncompetitive immunoassay for measurement of human plasma levels of monoclonal antibodies used for immunotherapy of cancers with KinExA⢠3200 biosensor
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Immunotherapy; Monoclonal antibodies; Bevacizumab; Cetuximab; Immunoassay; KinExA;
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Anal cancer; Immunotherapy; Nivolumab; Anti-EGFR; Cetuximab; Pembrolizumab; Panitumumab;
Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Cetuximab; Metastatic colon cancer; Elderly; Quality of life;
Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Radiotherapy; Head and neck cancer; Cetuximab; Durvalumab; Immunotherapy;
Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Cutaneous squamous cell carcinoma; Head and neck; Post-operative radiotherapy; Cetuximab; Survival;
Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Cisplatin; Cetuximab; Oropharyngeal neoplasms; Chemoradiotherapy; Head and neck cancer; Human papillomavirus; P16 protein; Oropharyngeal cancer; Dose fractionation; Radiotherapy; CRT; chemoradiation; DMFS; distant-metastasis-free survival; IR-RPA; interme
Comparison of high-dose Cisplatin-based chemoradiotherapy and Cetuximab-based bioradiotherapy for p16-positive oropharyngeal squamous cell carcinoma in the context of revised HPV-based staging
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Oropharyngeal squamous cell carcinoma; High-dose cisplatin; Cetuximab; p16-positive; Radiation therapy;
Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Nasopharyngeal carcinoma; IMRT; Concurrent chemoradiotherapy; Nimotuzumab; Cetuximab; Survival outcome; Adverse events;
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; EGFR exon 20 insertion; Afatinib; Cetuximab; NSCLC;
A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Afatinib; ErbB family blocker; Cetuximab; Solid tumours; Phase 1b;
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTALÂ and COIN-B trials in the ARCAD databa
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Left-sided colon cancer; Rectal cancer; Outcomes; Bevacizumab; Cetuximab;
Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; HNSCC; Elderly; Chemoradiation; Cetuximab; Radiation; Platinum overall survival;
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Metastatic colorectal cancer; Resection; Conversion therapy; Cetuximab; Bevacizumab; Surgery;
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Cetuximab; 5-FU; Oxaliplatin; mFOLFOX; Metastatic colorectal cancer;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Aflibercept; Bevacizumab; Cetuximab; Infection; Pertuzumab; Small-molecule inhibitors; Trastuzumab; Tyrosine kinase inhibitors; VEGF-targeted agents;
Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; VEGF-Grab; Cetuximab; Trastuzumab; Anti-angiogenic cancer therapy; Tumor targeting; Anti-EGFR cancer therapy;
Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Carcinoembryonic antigen; Cetuximab; Colon cancer; Diabetes mellitus; SGLT2 inhibitor;
Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Head and neck cancer; EGFR signalling; Annexin A1 (ANXA1); Formyl peptide receptor; Cetuximab; Exosomes; EGFR phosphorylation; miR-196a;
Efficient EFGR mediated siRNA delivery to breast cancer cells by Cetuximab functionalized Pluronic® F127/Gelatin
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Polymeric micelles; siRNA; AKT2; Cetuximab; Pluronic® F127; Gelatin; Breast cancer;
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; ADCC; Cetuximab; CTLA-4; PD-L1; PD-1; Immunotherapy;
Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; OSCC; Cetuximab; Resistance; BMP7; p-Smad1/5/8; DMH1;
Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Immunoliposomes; Cetuximab; Tumor growth; Squamous cell carcinoma; Animal model;
Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Recurrent head and neck cancer; Docetaxel; Cetuximab; Long term response; Complete response;
nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Cetuximab; Induction chemotherapy; Head and neck cancer;
A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Head and neck squamous cell carcinoma; Chemotherapy; Cetuximab; Cisplatin; 5-FU; Paclitaxel;
Full length articleSimple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; cetuximab; LC-MS/MS; proteomics; human serum; surrogate peptide; clinical application;
Experimental radiobiologyEGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Radiotherapy; Head and neck cancer; Biomarker; Cetuximab; Gene expression;
Bimodal fluorescence/129Xe NMR probe for molecular imaging and biological inhibition of EGFR in Non-Small Cell Lung Cancer
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Hyperpolarized xenon; NMR; Biosensor; Cetuximab; EGFR;
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Phase Ib; Afatinib; Cetuximab; NSCLC; EGFR;
SPECT imaging evaluation of 111indium-chelated cetuximab for diagnosing EGFR-positive tumor in an HCT-15-induced colorectal xenograft
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Cetuximab; Colorectal adenocarcinoma; Epidermal growth factor receptor; 111Indium;
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; EGFR; epidermal growth factor receptor; SFK; Src-family kinase; HNSCC; head and neck squamous cell carcinoma; IL6; interleukin-6; HGF; hepatocyte growth factor; VEGF; vascular endothelial growth factor; IRB; institutional review board; PD; progressive dis
Mini-reviewCo-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Colorectal cancer; Epidermal growth factor receptor; Autophagy; Endocytosis; Panitumumab; Cetuximab;
Original ResearchTreatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Metastatic colorectal cancer; Treatment strategy; K-RAS wild type; Cetuximab; Treatment sequence;
Original ArticleAP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; AP1G1; ASCT2; EGFR; Endocytosis; Cetuximab; AP1G1; adaptor-related protein complex 1 gamma 1 subunit; ASCT2; alanine-serine-cysteine transporter 2; ATP; adenosine triphosphate; DCA; dichloroacetate; EGFR; epidermal growth factor receptor; GFP; Green fluor
Therapeutic implication of mTORC2 in oral squamous cell carcinoma
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; mTORC2; Rictor; SGK1; Torin-1; Cetuximab;
Original ResearchImpact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; BRAF; RAS; Colorectal cancer; Bevacizumab; Cetuximab;
Original ArticleAcetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; ACC; AMPK; Cetuximab; EGFR; HIF-1; Warburg effect;
HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Cetuximab; EGFR; Gastrointestinal; Panitumumab; Targeted therapy;
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Cetuximab; Colorectal cancer; Liver metastases; Liver resection; Triplet chemotherapy;
The 'death pace' in the CO.17 trial
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Metastatic colorectal cancer; Cetuximab; Predictive factors;
A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Hedgehog signaling pathway; Phase 1; Cetuximab; Combination therapy; Head and neck squamous cell carcinoma;
Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Head and neck squamous cell carcinoma (HNSCC); Epidermal growth factor receptor (EGFR); Polymorphism; SNP; EGFR; CCDN1; FCGR2A; FCGR3A; KRAS-LCS6; Cetuximab; Toxicity;
Pre-operative chemoradiotherapy using capecitabine and cetuximab followed by definitive surgery in patients with operable rectal cancer
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Rectal cancer; Pre-operative chemoradiotherapy; Cetuximab; Capecitabine;
Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Oesophageal cancer; Oxaliplatin; Radiotherapy; Chemoradiotherapy; FOLFOX; Cetuximab;
Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Oropharyngeal cancer; Quality of life; Swallowing; Cetuximab; Chemo-RT
Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; Head and neck; Squamous cell carcinoma; Radiotherapy; Cetuximab; Chemoradiation; Targeted therapy; Anti-EGFR
ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; ASCT2; Glutathione; ROS; EGFR; Cetuximab; HNSCC;
ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models
Keywords: ستوکسیمب، اِربیتاکس، ستوکسیمب; ER2; Epidermal growth factor receptor; Monoclonal antibody; Non-small cell lung cancer; Cetuximab